Progyny, Inc. (NASDAQ:PGNY) Shares Sold by Rockefeller Capital Management L.P.

Rockefeller Capital Management L.P. trimmed its position in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 35.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 633,201 shares of the company's stock after selling 341,999 shares during the period. Rockefeller Capital Management L.P. owned approximately 0.70% of Progyny worth $10,627,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also bought and sold shares of PGNY. Pacer Advisors Inc. boosted its position in shares of Progyny by 12,579.4% in the 3rd quarter. Pacer Advisors Inc. now owns 2,492,642 shares of the company's stock worth $41,777,000 after purchasing an additional 2,472,983 shares in the last quarter. International Assets Investment Management LLC raised its stake in Progyny by 1,576.0% in the third quarter. International Assets Investment Management LLC now owns 2,565,118 shares of the company's stock valued at $42,991,000 after buying an additional 2,412,068 shares during the last quarter. Farallon Capital Management LLC boosted its holdings in Progyny by 120.8% in the second quarter. Farallon Capital Management LLC now owns 1,308,500 shares of the company's stock worth $37,436,000 after acquiring an additional 715,900 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in shares of Progyny by 24.8% during the second quarter. Dimensional Fund Advisors LP now owns 1,281,928 shares of the company's stock worth $36,676,000 after acquiring an additional 254,725 shares during the last quarter. Finally, Millennium Management LLC increased its holdings in shares of Progyny by 77.8% during the second quarter. Millennium Management LLC now owns 535,962 shares of the company's stock valued at $15,334,000 after acquiring an additional 234,590 shares in the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on PGNY shares. Jefferies Financial Group dropped their price objective on shares of Progyny from $31.00 to $24.00 and set a "buy" rating on the stock in a report on Thursday, September 19th. Leerink Partners reduced their price objective on Progyny from $25.00 to $21.00 and set a "market perform" rating for the company in a research note on Thursday, September 19th. Bank of America dropped their target price on Progyny from $22.00 to $21.00 and set a "buy" rating on the stock in a research report on Wednesday, November 13th. BTIG Research downgraded Progyny from a "buy" rating to a "neutral" rating in a research note on Wednesday, August 7th. Finally, Truist Financial reaffirmed a "hold" rating and set a $19.00 target price (down from $26.00) on shares of Progyny in a report on Wednesday, November 13th. Nine research analysts have rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Hold" and an average target price of $25.00.

Progyny Stock Performance

Shares of PGNY stock traded down $0.74 during trading hours on Tuesday, reaching $14.85. The company had a trading volume of 1,283,469 shares, compared to its average volume of 1,402,026. Progyny, Inc. has a 12-month low of $13.39 and a 12-month high of $42.08. The company has a market capitalization of $1.26 billion, a price-to-earnings ratio of 25.60, a PEG ratio of 1.80 and a beta of 1.35. The stock has a fifty day moving average of $15.79 and a 200-day moving average of $22.07.

Progyny (NASDAQ:PGNY - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported $0.11 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). The company had revenue of $286.63 million during the quarter, compared to analyst estimates of $296.85 million. Progyny had a return on equity of 11.36% and a net margin of 5.03%. The firm's revenue was up 2.0% compared to the same quarter last year. During the same period last year, the business earned $0.16 earnings per share. On average, analysts forecast that Progyny, Inc. will post 0.58 EPS for the current year.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.